HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulseâ"¢ technology using its proprietary Nanosecond Pulsed Field Ablationâ"¢ (nanosecond PFA or nsPFAâ"¢) energy, today announced late-breaking clinical study results from the nPulseâ"¢ Cardiac Surgical System first-in-human feasibility study at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting in Copenhagen, Denmark. The feasibility study is intended to assess the initial s. ...